قالب وردپرس درنا توس
Home https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ Health https://server7.kproxy.com/servlet/redirect.srv/sruj/smyrwpoii/p2/ New Study Says Breast Cancer is 11 Different Diseases, Allowing Researchers to Predict Relapse

New Study Says Breast Cancer is 11 Different Diseases, Allowing Researchers to Predict Relapse




<div _ngcontent-c14 = "" innerhtml = "

A new study has identified several cancerous diseases, each with a different risk of coming back after treatment. ] Getty

Nature New research published in the journal Nature & nbsp; shows that cancer is 11 genetically distinct diseases, and each has a different prognosis and chance of coming back after treatment. for breast cancer & nbsp; has increased dramatically in recent years, but unfortunately for some women, their breasts & nbsp; returns and spreads, becoming incurable. For some, this can be many years later – but it's impossible to accurately predict who is at risk of recurrence and who is all clear, " said Carlos Caldas, professor of cancer medicine at the Cancer Research UK Cambridge Institute and leader of the study

The study, which was also jointly led by Stanfor d University in California, examined genetic changes in breast tumors from 2,000 women, following them over 20 years to see whether or not the cancer returned. They then analyzed & nbsp; this data to create a tool that can be used in the future to predict which women are likely to be at high risk of relapse.

 

"In this study, we've delved into breast & nbsp; molecular subtypes & nbsp; so we can more accurately identify who might be at risk of relapsing and uncovering new ways of treating them," said Caldas.

Previous Research by the group showed that by analyzing the DNA or breast cancer, they can actually be considered to be distinct diseases. For example, triple-negative breast cancer, which has one of the worst prognoses, can actually be considered to be two different types of breast cancer. One of these subgroups has an initially poor prognosis, but if successfully treated, the disease is unlikely to come back in those who survived five years post-diagnosis.

Conversely, they found a group of patients with estrogen-receptor positive tumors who generally have a more favorable initial prognosis than those with triple-negative, but have a higher risk of very late relapse of disease up to 20 years post-diagnosis.

It is hoped that stratifying This is a more detailed way that can lead to better personalized medicine approaches, reducing the number of people who relapse as well as reassuring those with very low risk of relapse. But the test is not yet widely available.

“We are still able to offer this type of detailed molecular testing to all women, and we need more & nbsp; research & nbsp; to understand how we can tailor treatments to a patient's individual tumor biology. But this is incredibly encouraging progress, said Professor Karen Vousden, Cancer Research UK's chief scientist.

The team is currently developing an affordable test for use in hospitals and investigating better personalized treatment options for breast cancer patients. based on their findings. They hope to eventually run clinical trials using the test to stratify women to better treatment protocols fitting the precise genetic makeup of their tumors.

"

with a different risk of coming back after treatment Photo credit: Getty Getty

New research published in the journal Nature shows that breast cancer is 11 genetically distinct diseases, and each has a different prognosis and chance of coming back after treatment.

"Treatments for cancer have improved dramatically in recent years, but unfortunately for some women, their breast cancer returns and spreads, becoming incurable. For some, this can be many years later – but it's been impossible to accurately predict who is at risk of recurrence and who is all clear, "said Carlos Caldas, professor of cancer medicine at the Cancer Research UK Cambridge I

The study, which was also jointly led by Stanford University in California, examined genetic changes in breast tumors from 2,000 women, following them over 20 years to see whether or not the cancer returned. They can be used to create a tool that can be used in the future to predict which are likely to be at high risk of relapse

“In this study, we have delved into breast molecular subtypes so we can more accurately identify who might be at risk of relapsing and uncovering new ways of treating them, "said Caldas.

Previous research by the group showed that by analyzing the DNA of breast cancer, they can actually be considered to be distinct diseases. For example, triple-negative breast cancer, which has one of the worst prognoses, can actually be considered to be two different types of breast cancer. One of these subgroups has an initially poor prognosis, but if successfully treated, the disease is unlikely to come back in those who survived five years post-diagnosis.

Conversely, they found a group of patients with estrogen-receptor positive tumors who generally had more favorable initial prognosis than those with triple-neg. ative, but have a higher risk of very late relapse of disease up to 20 years post-diagnosis.

It is hoped that stratifying breast cancer patients in this more detailed way could lead to better personalized medicine approaches, reducing the number of people who relapse as well as reassuring those with very low risk of relapse. But the test is not yet widely available.

“We are still able to offer this type of detailed molecular testing to all women, and we need more research to understand how we can tailor treatments to a patient's individual. tumor biology. But this is incredibly encouraging progress, "said Professor Karen Vousden, Cancer Research UK's chief scientist.

The team is currently developing an affordable test for use in hospitals and investigating better personalized treatment options for breast cancer patients based on their findings. hope to eventually run clinical trials using the test to stratify women to better treatment protocols fitting the precise genetic makeup of their tumors.


Source link